Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12688461 | 1.00 | KMT2A (0.43) | KMT2AHTR2AHTR2CHTR7DRD2 | |
| SCHEMBL12688400 | 0.87 | KMT2A (0.44) | KMT2AHTR2AHTR2CHTR7DRD2 | |
| SCHEMBL1498292 | 0.79 | CCR2 (0.48) | HTR2AHTR7DRD2HTR6F2 | |
| SCHEMBL1498375 | 0.79 | CCR2 (0.48) | HTR2AHTR7DRD2HTR6F2 | |
| SCHEMBL1498290 | 0.79 | CCR2 (0.48) | HTR2AHTR7DRD2HTR6F2 | |
| SCHEMBL1782820 | 0.73 | CRBN (0.55) | KMT2AALDH1A1MEN1 | |
| SCHEMBL19692897 | 0.73 | HTR6 (0.43) | HTR7DRD2HTR6ALDH1A1HTR1D | |
| SCHEMBL29650200 | 0.73 | HTR6 (0.43) | HTR7DRD2HTR6ALDH1A1HTR1D | |
| SCHEMBL5549948 | 0.73 | ALDH1A1 (0.46) | KMT2AALDH1A1MMP2 | |
| SCHEMBL2535633 | 0.73 | CRBN (0.41) | ALDH1A1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | KMT2A 3950/4885HTR2A 737/4885HTR2C 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.